Abstract
High-intensity end-of-life (EoL) care for patients with cancer often includes multiple transitions to the hospital and intensive care unit (ICU) and is associated with adverse outcomes, such as declines in patient functional abilities
Funding Information
  • National Institute of Health (T32 CA 203703-8, CDP-2339-22, UL1TR002366)
  • Leukemia and Lymphoma Society (T32 CA 203703-8, CDP-2339-22, UL1TR002366)
  • National Center for Advancing Translational Sciences (T32 CA 203703-8, CDP-2339-22, UL1TR002366)

This publication has 50 references indexed in Scilit: